Regulating Cannabis: Women’s Perspective on State Legalization and its Impact

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), emphasized the necessity of regulating cannabis products to cope with the increasing acceptance of both medical and recreational marijuana use across states. In an interview with Fox News, Volkow stated, “I think that is crucial because, as you know, the majority of the states in the United States have legalized either recreational or medical marijuana.”

Recognizing the need to stay informed and minimize potential harm, Volkow stressed the importance of understanding the measures that can be taken to mitigate adverse effects. This includes regulating the sale of cannabis products and educating the public about the associated risks.

However, marijuana remains classified as a Schedule I drug under the federal Controlled Substances Act, limiting federal-level regulation possibilities. Volkow addressed recent research indicating a possible link between marijuana use and an increased risk of psychosis, stating, “Unfortunately, marijuana is not as benign as we would like it to be—because it would be great if it was a very safe drug.”

As a co-author of a study published in Psychological Medicine, Volkow highlighted the higher risk of developing schizophrenia in young men with cannabis use disorder. She emphasized the need for prevention, screening, and treatment of mental illnesses associated with cannabis use.

Interestingly, Volkow, a psychiatrist, acknowledged that there is currently no scientific evidence to prove harmful effects of occasional and moderate marijuana use among adults. She called for further research and evaluation to provide a clearer understanding of its impact.

In navigating the legalization of marijuana, it is essential to approach the topic from a women’s perspective, considering the potential health and societal implications that may disproportionately affect women.

Re-Reported from the story originally published in Benzinga.